XNAS · Healthcare · Biotechnology
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.18 | -0.22 | -22.22% | $982,000 | ❌ Miss | +0.00% | -7.20% | — |
| 2026-03-04 | Q4 2025 | -0.27 | -0.18 | +33.33% | $2.6M | ✅ Beat | -0.48% | +6.48% | -6.48% |
| 2025-11-12 |
| Q3 2025 |
| -0.34 |
| -0.28 |
| +17.65% |
| $2.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.31 | -0.28 | +9.68% | $3.1M | ✅ Beat | +5.59% | +0.60% | +10.78% |
| 2025-03-05 | Q4 2024 | -0.28 | -0.29 | -3.57% | $665,000 | ❌ Miss | +8.33% | -6.25% | -42.71% |
| 2024-08-12 | Q2 2024 | -0.28 | -0.28 | +0.00% | $536,000 | ➖ Inline | -2.33% | +0.00% | -5.17% |
| 2024-05-13 | Q1 2024 | -0.25 | -0.32 | -28.00% | $566,000 | ❌ Miss | +12.23% | +14.73% | +10.86% |
| 2024-03-06 | Q4 2023 | -0.29 | -0.21 | +27.59% | $7.2M | ✅ Beat | — | — | — |
Showing last 8 quarters.